AMGN
AmgenDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Bull: successful late-stage readouts, stable biologics demand, and continued buybacks drive EPS and multiple expansion toward the analyst high.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Biosimilar competition driving pricing/volume erosion
Momentum
37
Value
63
Sentiment
34
Setup hits (3d)
— · Net —
AI TargetsBase $333.98 · Bull $425.00 · Bear $180.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-23 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net —
Target $357.04
Why
Momentum37 · Δ7d -13.6
Value63 · Δ7d -0.2
Sentiment34 · Δ7d -3.4
So what
Weak posture. Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
37
26% active weight
Current posture
7d trendFlat
Δ7d
-13.6
Δ21d
-15.8
Value
63
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.0
Sentiment
34
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.4
Δ21d
-3.6
Why this grade
Composite grade D. Momentum 36.5 / Value 62.8 / Sentiment 34.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$197.69B
Beta
0.46
Shares Out
539.71M
P/E (TTM)
24.8
P/S (TTM)
4.80
P/FCF (TTM)
26.60
Rev YoY
+6.9%
EPS YoY
+4.6%
Gross Margin
+71.5%
Op Margin
+24.8%
Net Debt
$46.31B
Current Ratio
1.26
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology